The interferon-induced protein 35 (IFI35), also known as IFP35. is a cytoplasmic protein encoded by the *IFI35* gene in humans. It belongs to the interferon-stimulated gene (ISG) family, upregulated in response to type I and II interferons (IFNs) during viral infections and inflammatory processes. IFI35 is characterized by two conserved N-terminal dimerization domains (NID1 and NID2), facilitating oligomerization and interactions with other proteins. Functionally, it plays dual roles in innate immunity, acting as both a modulator of antiviral responses and a regulator of inflammatory signaling pathways. Studies suggest its involvement in nuclear factor-κB (NF-κB) and signal transducer and activator of transcription (STAT) pathways, influencing cytokine production and cell survival.
Antibodies targeting IFI35 are essential tools for investigating its expression, localization, and interactions. They are widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to study its role in viral infections (e.g., influenza, hepatitis), autoimmune diseases, and cancers. IFI35's expression is often dysregulated in malignancies, linking it to tumor progression or suppression. However, its precise mechanisms remain debated, highlighting the need for reliable antibodies to explore its context-dependent functions. Commercial IFI35 antibodies are typically developed in hosts like rabbits or mice, validated for specificity using knockout controls, and applied in both basic research and clinical biomarker studies.